Amanote Research
Register
Sign In
P1.01-111 EGFR Exon20 Insertion Patients Treated With First-Line Chemotherapy in Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.668
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
C. Zhao
X. Li
C. Su
X. Chen
S. Ren
C. Zhou
Publisher
Elsevier BV
Related search
Clinical Analysis of EGFR‐ Positive Non‐small Cell Lung Cancer Patients Treated With First‐line Afatinib: A Nagano Lung Cancer Research Group
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy
BMJ Open
Medicine
Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib
Oncology Letters
Cancer Research
Oncology
155P: PD-L1 Polymorphism Can Predict Clinical Outcomes of Non-Small Cell Lung Cancer Patients Treated With First-Line Paclitaxel–cisplatin Chemotherapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-85 the Prevalence of Different EGFR Exon20 Mutations in 12,833 Chinese Lung Cancer Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-15 First-Line Afatinib Dose Initiation and Adjustment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary